Latest news with #CorceptTherapeutics
Yahoo
7 days ago
- Business
- Yahoo
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday
We recently published a list of . In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other worst performers on Monday. Corcept Therapeutics dropped for a third consecutive day on Monday, shedding 7.58 percent to end at $71.68 apiece as investors appeared to have taken early profits from its intra-day surge. At intra-day trading, Corcept Therapeutics Incorporated (NASDAQ:CORT) rallied to as high as $86.02 following news that its pivotal Phase 3 ROSELLA trial for the treatment of ovarian cancer achieved its primary endpoint of improved progression-free survival. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Investors booked early profits to pull the company's share price down toward the end of the session. Corcept Therapeutics Incorporated (NASDAQ:CORT) said that patients who received relacorilant combined with nab-paclitaxel chemotherapy, experienced a 30 percent reduction in risk of disease progression, compared with patients who received nab-paclitaxel monotherapy. An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients' lives. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this drug developer would post earnings of $0.37 per share when it actually produced earnings of $0.26, delivering a surprise of -29.73%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Corcept , which belongs to the Zacks Medical - Drugs industry, posted revenues of $157.21 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 11.66%. This compares to year-ago revenues of $146.81 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Corcept shares have added about 44.4% since the beginning of the year versus the S&P 500's decline of -3.3%. While Corcept has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Corcept: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.40 on $216.49 million in revenues for the coming quarter and $1.76 on $905.68 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Xeris Biopharma (XERS), is yet to report results for the quarter ended March 2025. The results are expected to be released on May 8. This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Xeris Biopharma's revenues are expected to be $57.39 million, up 41.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Xeris Biopharma Holdings, Inc. (XERS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
02-06-2025
- Business
- Yahoo
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment
Corcept Therapeutics recently shared promising results from its Phase 3 ROSELLA trial, demonstrating a 30% reduction in disease progression risk for relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer. This advancement may have positively influenced the company's share price, which increased by 39% last quarter. Despite the Dow Jones slipping amid U.S.-China trade tensions, Corcept's stock performance appears resilient. Other updates, like the initiation of the BELLA trial and a share repurchase, would have further supported shareholder confidence and contributed to the positive overall return. You should learn about the 1 risk we've spotted with Corcept Therapeutics. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Corcept Therapeutics' recent announcement of the ROSELLA trial's success could play a significant role in shaping future revenue and earnings projections by potentially accelerating the approval process for relacorilant in oncology. This, combined with already planned expansions into hypercortisolism treatment, sets a promising narrative for entering new markets and increasing prescription volumes. However, challenges remain, such as ongoing patent litigation, which could impact generic competition and revenue. These developments have likely influenced the consensus price target, which stands at US$138.25, considerably above the current share price of US$70.74. Over the past five years, Corcept's total shareholder return has been very large, showcasing a substantial growth of 425.83%, which underscores the stock's impressive performance compared to both the broader market and its industry peers over a shorter one-year timeframe. Despite the broader market dynamics, Corcept has outperformed the US Pharmaceuticals industry, which saw a relative decline over the past year. Analysts forecast continuous revenue and earnings growth, underpinned by the expanding clinical specialist team and medical advancements. This ongoing confidence is reflected in the stock's performance, offering a discount to the analyst's price target, with expectations for future market positioning contributing to an optimistic outlook. Gain insights into Corcept Therapeutics' future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:CORT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Discover 3 Growth Stocks With Insider Ownership Up To 28%
Over the last 7 days, the United States market has experienced a 1.4% drop, but it remains up by 11% over the past year with earnings expected to grow by 14% annually in the coming years. In this context of fluctuating yet promising market conditions, growth stocks with significant insider ownership can be appealing as they often indicate confidence from those closest to the company's operations and potential for future success. Name Insider Ownership Earnings Growth Super Micro Computer (NasdaqGS:SMCI) 25.3% 39.1% Duolingo (NasdaqGS:DUOL) 14.3% 39.9% AST SpaceMobile (NasdaqGS:ASTS) 13.4% 67.1% FTC Solar (NasdaqCM:FTCI) 27.9% 61.8% Credo Technology Group Holding (NasdaqGS:CRDO) 12.1% 65.1% Astera Labs (NasdaqGS:ALAB) 15.2% 44.3% BBB Foods (NYSE:TBBB) 16.2% 30.2% Enovix (NasdaqGS:ENVX) 12.1% 58.4% Upstart Holdings (NasdaqGS:UPST) 12.5% 102.6% Eagle Financial Services (NasdaqCM:EFSI) 15.8% 82.8% Click here to see the full list of 189 stocks from our Fast Growing US Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★★☆ Overview: Corcept Therapeutics Incorporated focuses on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of $8.04 billion. Operations: The company's revenue is primarily derived from the discovery, development, and commercialization of pharmaceutical products, amounting to $685.45 million. Insider Ownership: 11.5% Corcept Therapeutics is poised for significant growth, with revenue expected to increase by 27.5% annually, outpacing the broader US market. Despite recent earnings showing a decline in net income to US$20.55 million for Q1 2025, the company maintains robust revenue guidance of US$900-950 million for the year. Corcept's strategic focus on cortisol modulation and its proprietary drug relacorilant shows promise in treating serious conditions like ovarian cancer and Cushing's syndrome, supported by successful clinical trials. Click here to discover the nuances of Corcept Therapeutics with our detailed analytical future growth report. According our valuation report, there's an indication that Corcept Therapeutics' share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★★ Overview: Astera Labs, Inc. designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure with a market cap of $15.20 billion. Operations: The company generates $490.47 million in revenue from its semiconductor-based connectivity solutions for cloud and AI infrastructure. Insider Ownership: 15.2% Astera Labs is experiencing rapid growth, with earnings projected to rise significantly at 44.3% annually and revenue expected to grow at 24% per year, both surpassing US market averages. Despite recent insider selling, the company's collaboration with NVIDIA on AI infrastructure solutions highlights its strategic positioning in advanced connectivity technologies. Recent announcements include a Q1 net income of US$31.82 million from sales of US$159.44 million, marking a turnaround from previous losses. Take a closer look at Astera Labs' potential here in our earnings growth report. Our valuation report unveils the possibility Astera Labs' shares may be trading at a premium. Simply Wall St Growth Rating: ★★★★★☆ Overview: CoreWeave, Inc. operates a cloud platform focused on scaling, support, and acceleration for GenAI with a market cap of $51.54 billion. Operations: The company's revenue is primarily derived from its data processing segment, which generated $2.71 billion. Insider Ownership: 28.7% CoreWeave's recent $2 billion debt offering, alongside a $4 billion cloud computing deal with OpenAI, underscores its strategic growth in AI infrastructure. Despite high share price volatility and significant insider selling over the past three months, CoreWeave's revenue is forecast to grow at 37.3% annually, outpacing the US market. The company's financial maneuvers aim to enhance flexibility for expanding its AI cloud platform globally while maintaining a focus on technological innovation and partnerships. Delve into the full analysis future growth report here for a deeper understanding of CoreWeave. Our expertly prepared valuation report CoreWeave implies its share price may be too high. Embark on your investment journey to our 189 Fast Growing US Companies With High Insider Ownership selection here. Searching for a Fresh Perspective? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include NasdaqCM:CORT NasdaqGS:ALAB and NasdaqGS:CRWV. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements
The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market. LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cushing's Disease Market Report According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024. In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034). Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years. The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others. In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism. In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026. In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome. Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies. Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years. Cushing's Disease Epidemiology Segmentation The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Cushing's Disease Total Diagnosed Prevalent Cases of Cushing's Disease Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease Age-Specific Diagnosed Prevalent Cases of Cushing's Disease Cushing's Disease Treatment Market The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels. Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include SIGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma. SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route. Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900). RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action. To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management Cushing's Disease Pipeline Therapies and Key Companies Relacorilant (CORT125134): Corcept Therapeutics Clofutriben (SPI-62): Sparrow Pharmaceuticals Atumelnant (CRN04894): Crinetics Pharmaceuticals Lu AG13909: H. Lundbeck ST-002: Stero Therapeutics Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials Cushing's Disease Market Dynamics The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR. Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM. However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies. Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth. Cushing's Disease Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan]. Cushing's Disease Market Size in 2024 USD 1 Billion Key Cushing's Disease Companies Xeris Pharmaceuticals, Recordati, Corcept Therapeutics, Sparrow Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others Key Cushing's Disease Therapies RECORLEV, ISTURISA, SIGNIFOR, SIGNIFOR LAR, KORLYM, Relacorilant, Clofutriben, Lu AG13909, ST-002, Atumelnant, and others Scope of the Cushing's Disease Market Report Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Cushing's Disease Market Overview at a Glance 6.1 Market Share (%) Distribution by Therapies of Cushing's Disease in 2024 6.2 Market Share (%) Distribution by Therapies of Cushing's Disease in 2034 7 Disease Background and Overview 7.1 Introduction 7.2 Clinical and Biological Characteristics 7.3 Genetics of Cushing's Disease 7.4 Pathogenesis and Pathophysiology 7.5 Complications of Cushing's Disease 7.6 Diagnosis of Cushing's Disease 7.6.1 Diagnostic Algorithm 7.7 Treatment and Management of Cushing's Disease 7.7.1 Treatment Algorithm of Cushing's Disease 8 Guidelines, Recommendations, and Management for Cushing's Disease 8.1 Consensus on Diagnosis and Management of Cushing's Disease: A Guideline Update (2020) (The United States) 8.2 Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline (2015) (Europe) 8.3 Clinical Significance of Screening for Subclinical Cushing's Disease in Patients With Pituitary Tumors (2010) (Japan) 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationales 9.3 Total Diagnosed Prevalent Cases of Cushing's Disease in the 7MM 9.4 The United States 9.4.1 Total Diagnosed Prevalent Cases of Cushing's Disease in the US 9.4.2 Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in the US 9.4.3 Age-specific Diagnosed Prevalent Cases of Cushing's Disease in the US 9.5 EU4 and the UK 9.5.1 Total Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK 9.5.2 Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK 9.5.3 Age-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK 9.6 Japan 9.6.1 Total Diagnosed Prevalent Cases of Cushing's Disease in Japan 9.6.2 Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan 9.6.3 Age-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan 10 Patient Journey 11 Marketed Drug 11.1 Marketed Drug Details 11.2 ISTURISA (osilodrostat): Recordati 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Clinical Development Activities 11.2.4.1 Clinical Trials Information 11.2.5 Safety and Efficacy 11.3 RECORLEV (levoketoconazole): Xeris Pharmaceuticals 11.3.1 Product Description 11.3.2 Regulatory Milestones 11.3.3 Other Developmental Activities 11.3.4 Safety and Efficacy 11.4 SIGNIFOR (pasireotide): Recordati 11.4.1 Product Description 11.4.2 Regulatory Milestones 11.4.3 Other Developmental Activities 11.4.4 Safety and Efficacy 11.5 SIGNIFOR LAR (pasireotide pamoate): Recordati 11.5.1 Product Description 11.5.2 Regulatory Milestones 11.5.3 Other Developmental Activities 11.5.4 Safety and Efficacy 12 Emerging Drugs 12.1 Key Cross Competition 12.2 Relacorilant (CORT125134): Corcept Therapeutics 12.2.1 Product Description 12.2.2 Other Development Activity 12.2.3 Clinical Development 12.2.3.1 Clinical Trial Information 12.2.4 Safety and Efficacy 12.3 Clofutriben (SPI-62): Sparrow Pharmaceuticals 12.3.1 Product Description 12.3.2 Other Development Activity 12.3.3 Clinical Development 12.3.3.1 Clinical Trial Information 12.3.4 Safety and Efficacy 12.4 Atumelnant (CRN04894): Crinetics Pharmaceuticals 12.4.1 Product Description 12.4.2 Other Development Activity 12.4.3 Clinical Development 12.4.3.1 Clinical Trial Information 12.4.4 Safety and Efficacy 13 Cushing's Disease: Seven Major Market Analysis 13.1 Key Findings 13.2 Market Outlook 13.3 Key Market Forecast Assumptions 13.3.1 Cost Assumptions and Rebates 13.3.2 Pricing Trends 13.3.3 Analogue Assessment 13.3.4 Launch Year and Therapy Uptakes 13.4 Conjoint Analysis 13.5 Total Market Size of Cushing's Disease in the 7MM 13.6 Market Size of Cushing's Disease by Therapies in 7MM 13.7 The United States 13.7.1 Total Market Size of Cushing's Disease in the US 13.7.2 Market Size of Cushing's Disease by Therapies in the US 13.8 EU4 and the UK 13.8.1 Total Market Size of Cushing's Disease in the EU4 and the UK 13.8.2 Market Size of Cushing's Disease by Therapies in EU4 and the UK 13.9 Japan 13.9.1 Total Market Size of Cushing's Disease in Japan 13.9.2 The Market Size of Cushing's Disease by Therapies in Japan 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 17.1 The United States 17.1.1 Centre for Medicare and Medicaid Services (CMS) 17.2 EU4 and the UK 17.2.1 Germany 17.2.2 France 17.2.3 Italy 17.2.4 Spain 17.2.5 United Kingdom 17.3 Japan 17.3.1 MHLW 17.4 Market Access and Reimbursement of Cushing's Disease 18 Appendix 18.1 Bibliography 18.2 Report Methodology 19 DelveInsight Capabilities 20 Disclaimer 21 About DelveInsight Related Reports Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Cushing's Syndrome Pipeline Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Endogenous Cushing's Syndrome Market Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. Endogenous Cushing's Syndrome Pipeline Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP
